Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)

Gastric Cancer

Volumn 14, Issue 1, 2011, Pages 72-80

  Narahara, Hiroyuki ^a   Iishi, Hiroyasu ^b   Imamura, Hiroshi ^c   Tsuburaya, Akira ^d   Chin, Keisho ^e   Imamoto, Haruhiko ^f   Esaki, Taito ^g   Furukawa, Hiroshi ^c   Hamada, Chikuma ^h   Sakata, Yuh ⁱ  

^a HIROSHIMA UNIVERSITY   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c SAKAI MUNICIPAL HOSPITAL   (Japan)

^d KANAGAWA CANCER CENTER   (Japan)

^e CANCER INSTITUTE HOSPITAL   (Japan)

^f KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g NATIONAL KYUSHU CANCER CENTER   (Japan)

^h TOKYO UNIVERSITY OF SCIENCE   (Japan)

ⁱ Misawa Municipal Hospital   (Japan)

Author keywords

Gastric cancer; Irinotecan S 1; Phase III; Randomized controlled trial

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; IRINOTECAN; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN MANIFESTATION; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DISEASE PROGRESSION; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OXONIC ACID; STOMACH NEOPLASMS; TEGAFUR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79953025190     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-011-0009-5     Document Type: Article

References (35)

1. Foundation for Promotion of Cancer Research. Cancer Statistics in Japan 2007. Available from URL http://ganjoho.ncc.go.jp/public/statistics/backnumber/ 2007-en.html. Accessed June 21, 2010.
2. K Maruyama M Kaminishi K Hayashi Y Isobe I Honda H Katai, et al. 2006 Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry Gastric Cancer 9 51 66 16767357 10.1007/s10120-006-0370-y (Pubitemid 43890701)
3. U Vanhoefer P Rougier H Wilke MP Ducreux AJ Lacave E Van Cutsem, et al. 2000 Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group J Clin Oncol 18 2648 2657 10894863 1:CAS:528:DC%2BD3cXls12iurk%3D (Pubitemid 30465650)
4. M Dank J Zaluski C Barone V Valvere S Yalcin C Peschel, et al. 2008 Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction Ann Oncol 19 1450 1457 18558665 10.1093/annonc/mdn166 1:STN:280: DC%2BD1cvotFCmtA%3D%3D
5. JA Ajani VM Moiseyenko S Tjulandin A Majilis M Constenla C Boni, et al. 2007 Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group J Clin Oncol 25 3205 3209 17664467 10.1200/JCO.2006.10.4968 1:CAS:528:DC%2BD2sXhtVWqs73E (Pubitemid 47333732)
6. JA Ajani W Rodriguez G Bodoky CM Moiseyenko M Lichinitser V Gorbunova, et al. 2010 Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial J Clin Oncol 28 1547 1553 20159816 10.1200/JCO.2009.25.4706 1:CAS:528:DC%2BC3cXltFGhtr0%3D
7. JS Waters A Norman D Cunningham JH Scarffe A Webb P Harper, et al. 1999 Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial Br J Cancer 80 269 272 10390007 10.1038/sj.bjc.6690350 1:CAS:528:DyaK1MXjtFyksbo%3D (Pubitemid 29210117)
8. D Cunningham N Starling S Rao T Iveson M Nicolson F Coxon, et al. 2008 Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 36 46 18172173 10.1056/NEJMoa073149 1:CAS:528:DC%2BD1cXisFSktg%3D%3D
9. A Ohtsu Y Shimada K Shirao N Boku I Hyodo H Saito, et al. 2003 Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205) J Clin Oncol 21 54 59 12506170 10.1200/JCO.2003.04.130 1:CAS:528:DC%2BD2cXpsVWru7k%3D
10. M Fukushima H Satake J Uchida Y Shimamoto T Kato T Takechi, et al. 1998 Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts Int J Oncol 13 693 698 9735397 1:CAS:528: DyaK1cXmsVClurw%3D
11. W Koizumi M Kurihara S Nakano K Hasegawa 2000 Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group Oncology 58 191 197 10765119 10.1159/000012099 1:CAS:528:DC%2BD3cXjvVeitr4%3D (Pubitemid 30189900)
12. Y Sakata A Ohtsu N Horikoshi K Sugimachi Y Mitachi T Taguchi 1998 Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715 1720 9893658 10.1016/S0959-8049(98)00211-1 1:CAS:528:DyaK1cXntlShurw%3D (Pubitemid 28474225)
13. N Boku S Yamamoto H Fukuda K Shirao T Doi A Sawaki, et al. 2009 Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study Lancet Oncol 10 11 1027 1028 10.1016/S1470-2045(09)70259-1
14. S Sakuramoto M Sasako T Yamaguchi T Kinoshita M Fujii A Nashimoto, et al. 2007 Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 1810 1820 17978289 10.1056/NEJMoa072252 1:CAS:528:DC%2BD2sXht1Kit7bI (Pubitemid 350044801)
15. JA Ajani J Faust K Ikeda JC Yao H Anbe KL Carr, et al. 2005 Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma J Clin Oncol 23 6957 6965 16145066 10.1200/JCO.2005.01.917 1:CAS:528:DC%2BD2MXhtFCrsbjM
16. W Koizumi S Tanabe K Saigenji A Ohtsu N Boku F Nagashima, et al. 2003 Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer Br J Cancer 89 2207 2212 14676796 10.1038/sj.bjc.6601413 1:CAS:528:DC%2BD3sXpvVShtbc%3D (Pubitemid 38168001)
17. K Yoshida M Ninomiya N Takakura N Hirabayashi W Takiyama Y Sato, et al. 2006 Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer Clin Cancer Res 12 3402 3407 16740764 10.1158/1078-0432.CCR-05-2425 1:CAS:528:DC%2BD28XltFyis7k%3D
18. H Narahara K Fujitani H Takiuchi N Sugimoto K Inoue N Uedo, et al. 2008 Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer Oncology 74 37 41 18544958 10.1159/000138978 1:CAS:528:DC%2BD1cXnvFSjs70%3D (Pubitemid 351915008)
19. N Uedo H Narahara R Ishihara H Takiuchi M Goto K Fujitani, et al. 2007 Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002) Oncology 73 65 71 18334851 10.1159/000120630 1:CAS:528:DC%2BD1cXktVSgt74%3D (Pubitemid 351465602)
20. W Koizumi H Narahara T Hara A Takagane T Akiya M Takagi, et al. 2008 S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 2 10.1016/S1470- 2045(08)70035-4
21. H Takiuchi H Narahara T Tsujinaka M Gotoh S Kawabe K Katsu, et al. 2005 Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002) Jpn J Clin Oncol 35 520 525 16141295 10.1093/jjco/hyi148 (Pubitemid 41573941)
22. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280: DC%2BD3c7it1Gitg%3D%3D
23. M Inokuchi T Yamashita H Yamada K Kojima W Ichikawa Z Nihei, et al. 2006 Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer Br J Cancer 94 1130 1135 16570038 10.1038/sj.bjc.6603072 1:CAS:528:DC%2BD28XjsFaksLo%3D
24. GJ Peters CL van der Wilt CJ van Moorsel JR Kroep AM Bergman SP Ackland 2000 Basis for effective combination cancer chemotherapy with antimetabolites Pharmacol Ther 87 227 253 11008002 10.1016/S0163-7258(00)00086-3 1:CAS:528:DC%2BD3cXmslOjtbY%3D
25. S Guichard I Hennebelle R Bugat P Canal 1998 Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line Biochem Pharmacol 55 667 676 9515577 10.1016/S0006-2952(97)00541-8 1:CAS:528:DyaK1cXnvVamsg%3D%3D (Pubitemid 28077825)
26. Y Yamada H Yasui A Goto T Arai T Ura T Hamaguchi, et al. 2003 Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer Int J Clin Oncol 8 374 380 14663640 10.1007/s10147-003-0359-z 1:CAS:528:DC%2BD3sXps1SgsLg%3D (Pubitemid 38040051)
27. Y Komatsu S Yuki T Miyagishima M Asaka 2006 Irinotecan plus oral S-1 in patients with advanced gastric cancer biweekly IRIS regimen Gan To Kagaku Ryoho (Cancer and Chemotherapy) 33 Suppl 1 131 134 1:CAS:528:DC%2BD28Xns1Wjsb4%3D (in Japanese)
28. Van Cutsem E, Kang Y, Chung H, Shen L, Sawaki A, Lordick F, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC) [abstract]. J Clin Oncol. 2009;27(Suppl 18S):LBA4509.
29. PC Enzinger DH Ilson LB Saltz EM O'Reilly DP Kelsen 1998 Irinotecan and cisplatin in upper gastrointestinal malignancies Oncology 12 110 113 9726102 1:STN:280:DyaK1czpsVWltw%3D%3D (Pubitemid 28518499)
30. N Boku A Ohtsu Y Shimada K Shirao S Seki H Saito, et al. 1999 Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer J Clin Oncol 17 319 323 10458249 1:CAS:528:DyaK1MXltVyrtg%3D%3D (Pubitemid 29022409)
31. C Pozzo C Barone J Szanto E Padi I Peschel J Bukki, et al. 2004 Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study Ann Oncol 15 1773 1781 15550582 10.1093/annonc/mdh473 1:STN:280:DC%2BD2crotVGitw%3D%3D (Pubitemid 40017161)
32. Thuss-Patience PC, Kretzschmar A, Deist T, Hinke A, Bichev D, Lebedinzew B, et al. Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) [abstract]. J Clin Oncol. 2009; 27 (Suppl 15S):4540.
33. D Takahari Y Shimada S Takeshita H Nishitani A Takashima N Okita, et al. 2010 Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer Gastric Cancer 13 186 190 20820988 10.1007/s10120-010-0557-0 1:CAS:528:DC%2BC3cXhtFWqsbfP
34. T Sakamoto H Yasui N Boku Y Onozawa S Hironaka A Fukutomi, et al. 2010 Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis Int J Clin Oncol 15 287 293 20217447 10.1007/s10147-010-0054-9 1:CAS:528:DC%2BC3cXntlKkt7s%3D
35. Y Ando K Fujita Y Sasaki Y Hasegawa 2007 UGT1A1 6 and UGT1A1 27 for individualized irinotecan chemotherapy Curr Opin Mol Ther 9 258 262 17608024 1:CAS:528:DC%2BD2sXotV2gtbY%3D (Pubitemid 46944317)